HSBC Holdings
PRLD icon

HSBC Holdings’s Prelude Therapeutics PRLD Stock Holding History

HSBC Holdings’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.9K Hold
13,652
– – ﹤0.01% 2809
2025
Q4 		$39.5K Sell
13,652
-95
-0.7% -$160 ﹤0.01% 2876
2025
Q3 		$20.2K Sell
13,747
-3,664
-21% -$3.67K ﹤0.01% 2673
2025
Q2 		$13.9K Sell
17,411
-3,219
-16% -$2.79K ﹤0.01% 2990
2025
Q1 		$17.5K Sell
20,630
-10
-0% -$9 ﹤0.01% 2973
2024
Q4 		$25.6K Sell
20,640
-132
-0.6% -$175 ﹤0.01% 3044
2024
Q3 		$43.8K Sell
20,772
-4,133
-17% -$19.1K ﹤0.01% 2891
2024
Q2 		$90.7K Hold
24,905
– – ﹤0.01% 2747
2024
Q1 		$118K Buy
24,905
+1,695
+7% +$6.59K ﹤0.01% 2814
2023
Q4 		$93.8K Buy
23,210
+12
+0.1% +$37 ﹤0.01% 2605
2023
Q3 		$70.8K Buy
+23,198
New +$87K ﹤0.01% 2595

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HSBC Holdings's PRLD Position: Q1 2026 in Review

HSBC Holdings held its Prelude Therapeutics (PRLD) position steady in Q1 2026 at 13,652 shares worth $47.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2809.

HSBC Holdings first reported a position in PRLD in Q3 2023 and has held it in 11 quarters since. The position peaked at $118K in Q1 2024. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • HSBC Holdings held 13,652 shares of Prelude Therapeutics worth $47.9K as of Q1 2026.
  • HSBC Holdings left its Prelude Therapeutics share count unchanged in Q1 2026.
  • Prelude Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2809 holding.
  • HSBC Holdings first reported a position in Prelude Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • HSBC Holdings's Prelude Therapeutics position peaked at $118K in Q1 2024.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.